In patients with cirrhosis, rifaximin has been demonstrated to increase mean arterial pressure and GFR, while decreasing plasma endotoxin, serum interleukin-6, and serum tumor necrosis factor-α [16]. The gene discussed is TNF; the disease is Cirrhosis.